BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics
September 12 2023 - 9:00AM
BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX”
or the “Company”) (NASDAQ: BRTX ), a clinical stage
company focused on stem cell-based therapies, today announced that
it has entered into a supply agreement with Evolutionary Biologics,
a supplier of biologic-based cosmetics.
Pursuant to the supply agreement,
BioRestorative, using its cGMP ISO-7 certified clean room, will
manufacture tissue-based biologics for Evolutionary Biologics for
cosmetic and aesthetic applications. The first-generation product,
that has been formulated and manufactured, is an umbilical cord
tissue extract that is highly enriched with factors that address
the signs of aging. These factors include cytokines, chemokines,
growth factors and exosomes, which are known to play important
roles as communication mediators between cells and have been found
to have certain anti-aging effects on skin.
Founded in 2020 by former L'Oreal President, Jim
Morrison, Evolutionary Biologics is a supplier of cosmetic-focused
biologics for plastic surgeons, dermatologists and medical spas
across the United States.
With the Company’s expanded manufacturing
capabilities, BioRestorative is able to support research and
development of biologics from various aspects, especially for
exosome manufacturing, engineering, quality control and potential
therapeutic applications.
“This is a very exciting time for BioRestorative
Therapies as we seek to develop our recent strategic partnerships.
Leveraging our ISO-7 certified clean room to formulate and
manufacture a commercial product in the $62.8 billion global
aesthetics market is not only a thrilling opportunity but it allows
us to scale and drive efficiencies going forward as we seek to
expand our commercial business model. By no means does this venture
disrupt or diminish our clinical stage platforms; rather it helps
to provide additional resources and financial support to these
ongoing programs. If our initial order is received well in the
commercial marketplace, then we can look forward to possible future
opportunities at a much larger scale. If accomplished, this would
result in significant improvement in our financial condition and
liquidity and would make us far less dependent on the fragile
capital markets”, stated Lance Alstodt, Chief Executive Officer of
BioRestorative.
Jim Morrison, Chief Executive Officer of
Evolutionary Biologics, a division of Emergent Health Corp, (EMGE)
stated “we are very excited to be working with Biorestorative
Therapies. They are a world class manufacturer of biological
products, and operate a state-of-the-art Laboratory and
manufacturing facility. This partnership will undoubtedly provide
Evolutionary Biologics with a competitive advantage in the
large and fast-growing biologics cosmetic marketplace".
About BioRestorative
Therapies, Inc.
BioRestorative Therapies, Inc.
( www.biorestorative.com ) develops therapeutic products
using cell and tissue protocols, primarily involving adult stem
cells. Our two core programs, as described below, relate to the
treatment of disc/spine disease and metabolic disorders:
• Disc/Spine Program (brtxDISC™): Our lead cell
therapy candidate, BRTX-100, is a product formulated from
autologous (or a person’s own) cultured mesenchymal stem cells
collected from the patient’s bone marrow. We intend that the
product will be used for the non-surgical treatment of painful
lumbosacral disc disorders or as a complementary therapeutic to a
surgical procedure. The BRTX-100 production process utilizes
proprietary technology and involves collecting a patient’s bone
marrow, isolating and culturing stem cells from the bone marrow and
cryopreserving the cells. In an outpatient procedure, BRTX-100 is
to be injected by a physician into the patient’s damaged disc. The
treatment is intended for patients whose pain has not been
alleviated by non-invasive procedures and who potentially face the
prospect of surgery. We have commenced a Phase 2 clinical trial
using BRTX-100 to treat chronic lower back pain arising from
chronic lumbar disc disease. We are also investigating the
expansion of the clinical application of BRTX-100 to other
indications within the body.
• Metabolic Program (ThermoStem®): We are
developing a cell-based therapy candidate to target obesity and
metabolic disorders using brown adipose (fat) derived stem cells to
generate brown adipose tissue (“BAT”). BAT is intended to mimic
naturally occurring brown adipose depots that regulate metabolic
homeostasis in humans. Initial preclinical research indicates that
increased amounts of brown fat in animals may be responsible for
additional caloric burning as well as reduced glucose and lipid
levels. Researchers have found that people with higher levels of
brown fat may have a reduced risk for obesity and diabetes.
Forward-Looking Statements
This press release contains "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The words “believe,” “look
forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,”
“should,” “plan,” “could,” “target,” “potential,” “is likely,”
“will,” “expect” and similar expressions, as they relate to us, are
intended to identify forward-looking statements. Forward-looking
statements in this press release include, but are not limited to,
statements regarding the anticipated closing of the offering and
the intended use of proceeds. You are cautioned that such
statements are subject to a multitude of risks and uncertainties
that could cause future circumstances, events or results to differ
materially from those projected in the forward-looking statements
as a result of various factors and other risks, including, without
limitation, those set forth in the Company's latest Form 10-K filed
with the Securities and Exchange Commission. You should consider
these factors in evaluating the forward-looking statements included
herein, and not place undue reliance on such statements. The
forward-looking statements in this release are made as of the date
hereof and the Company undertakes no obligation to update such
statements.
Investor Contact:
Email: ir@biorestorative.com
BioRestorative Therapies (NASDAQ:BRTX)
Historical Stock Chart
From Apr 2024 to May 2024
BioRestorative Therapies (NASDAQ:BRTX)
Historical Stock Chart
From May 2023 to May 2024